SCREENING OF ARQULE COMPOUNDS. During the Array Screening Period, Abbott shall have the right, either directly or through Abboxx'x Xxxiliates or third party contractors selected by Abbott, to perform such testing and analytical work as Abbott deems appropriate on ArQule Core Compounds received hereunder, provided that Abboxx xxxll have the right to perform composition and structural analysis only after Abboxx'x xxxeipt of confirmed chemical composition and structure and purity information pursuant to Section 5.3, and further provided that Abboxx xxxll not perform significant derivitization work on ArQule Core Compounds until Abboxx xxxes a Target Reservation for the ArQule Array containing such ArQule Core Compounds pursuant to Section 5.5. The parties agree that "significant derivitization work" shall mean any derivitization work beyond that which is reasonably necessary to allow Abboxx xx determine whether an ArQule Core Compound is sufficiently amenable to chemical modification to warrant the exercise of a Target Reservation by Abboxx.
SCREENING OF ARQULE COMPOUNDS. ArQule hereby grants to Abbott and its Affiliates a nonexclusive, worldwide, royalty-free license (without the right to sublicense or subcontract) during the term of this Agreement and thereafter to perform such testing and analytical work as Abbott deems appropriate on ArQule Core Compounds delivered by ArQule hereunder. Notwithstanding the foregoing, Abbott may, during the term of this Agreement and thereafter, deliver ArQule Core Compounds to one or more third parties so as to allow such third parties to perform testing and analytical work on such ArQule Core Compounds provided that, prior to delivering any ArQule Core Compounds to any such third party, Abbott, ArQule and each such third party enter into a materials transfer agreement substantially in the form of the attached EXHIBIT B or such other form as may be acceptable to ArQule. At the time of delivery, ArQule will identify the Chemical Theme of each ArQule Array delivered to Abbott but not the structures of the * confidential treatment has been requested for marked portions individual ArQule Core Compounds in such ArQule Arrays. Initially, Abboxx xxxl not disclose the targets against which such ArQule Arrays are screened. If Abbott detects any Active ArQule Compound in an ArQule Array, it will promptly notify ArQule. ArQule shall then determine if such Active ArQule Compound and any Active ArQule Homolog thereto have been previously committed to a Third Party Mapping Array Partner or to a bona fide, documented internal ArQule program (including programs with academic collaborators). ArQule will disclose to Abbott (a) the structure of such Active ArQule Compound if it has not been so committed and all Active ArQule Homologs thereto (if any) that have not been so committed and (b) the structures, but not the locations in the ArQule Array, of all other ArQule Compounds in such ArQule Array and Abbott will disclose to ArQule (a) the identity of the biological target as to which activity was detected and (b) the level of activity exhibited by such Active ArQule Compound and such Active ArQule Homolog (the date of such mutual disclosure being referred to herein as the "Mutual Disclosure Date"). All such disclosed information shall be treated as Confidential Information by the receiving party in accordance with Article 8."
SCREENING OF ARQULE COMPOUNDS. During any Research Period, Monsanto shall have the right, either directly or through Monsanto's Primary Affiliates or third parties (including Secondary Affiliates who are not also Primary Affiliates) selected by Monsanto, to perform such testing as Monsanto deems appropriate on ArQule Compounds and ArQule Derivative Compounds received hereunder, provided that, prior to delivering any ArQule Compounds or ArQule Derivative Compounds to any such third party(including Secondary Affiliates who are not also Primary Affiliates), Monsanto, ArQule and each such third party(including Secondary Affiliates who are not also Primary Affiliates) enter into a Materials Transfer Agreement substantially in the form of the attached Exhibit B.
SCREENING OF ARQULE COMPOUNDS. Subject to the terms and conditions of this Agreement, ArQule hereby grants PRI and its Affiliates a nonexclusive, worldwide license (without the right to sublicense) under the ArQule Patent Rights and other rights in ArQule Technology to screen the ArQule Compounds in the Compass Array Sets and Mapping Array Sets against any Targets within the Screening Field. PRI agrees to use efforts consistent with its normal scientific practices to screen the ArQule Compounds in ----------------------------- *Confidential Treatment has been requested for the marked portion.
SCREENING OF ARQULE COMPOUNDS. During the Research Period, and subject to the screening licenses granted in Section 4.1. above, Searxx xxxll have the right, either directly or through Searxx'x Xxxmary Affiliates or third parties selected by Searxx, xx perform such testing in the Field as Searxx xxxms appropriate on ArQule Compounds and ArQule Derivative Compounds, provided that, prior to delivering any ArQule Compounds or ArQule Derivative Compounds to any such third party, Searxx, XxQule and each such third party enter into a materials transfer agreement reasonably acceptable to ArQule and including terms and conditions that are usual and customary for such agreements, and further provided that Searxx xxxll not identify the compounds provided to any third party as ArQule Compounds.
SCREENING OF ARQULE COMPOUNDS. Subject to the terms and conditions of this Agreement, ArQule hereby grants PRI and its Affiliates a nonexclusive, worldwide license (without the right to sublicense) under the ArQule Patent Rights and other rights in ArQule Technology to screen the ArQule Compounds in the Compass Array Sets and Mapping Array Sets against any Targets within the Screening Field. PRI agrees to use efforts consistent with its normal scientific practices to screen the ArQule Compounds in the Compass Array Sets and Mapping Array Sets against its Targets in the Screening Field.
SCREENING OF ARQULE COMPOUNDS. During the Research Period, Monsanto shall have the right, either directly or through Monsanto's Primary Affiliates or third parties selected by Monsanto, to perform such testing in the Field as Monsanto deems appropriate on ArQule Compounds and ArQule Derivative Compounds, provided that, prior to delivering any ArQule Compounds or ArQule Derivative Compounds to any such third party, Monsanto, ArQule and each such third party enter into a materials transfer agreement reasonably acceptable to ArQule and including terms and conditions that are usual and customary for such agreements, and further provided that Monsanto shall not identify the compounds provided to any third party as ArQule Compounds.
